Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Company profile
Ticker
NVCR
Exchange
Website
CEO
Asaf Danziger
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Novocure Austria GmbH • Novocure Canada, Inc. • Novocure Denmark ApS • NovoCure (Israel) Ltd. • Novocure France SAS • Novocure GmbH • Novocure Inc. • Novocure Italy S.r.L. • Novocure K.K. • Novocure Netherlands B.V. ...
NVCR stock data
Analyst ratings and price targets
Latest filings (excl ownership)
S-8
Registration of securities for employees
23 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
23 Feb 23
8-K
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
9 Jan 23
8-K
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
5 Jan 23
8-K
Other Events
4 Nov 22
8-K
Novocure Reports Third Quarter 2022 Financial Results
27 Oct 22
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Novocure Reports Second Quarter 2022 Financial Results
28 Jul 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
Transcripts
NVCR
Earnings call transcript
2022 Q4
23 Feb 23
NVCR
Earnings call transcript
2022 Q3
27 Oct 22
NVCR
Earnings call transcript
2022 Q2
28 Jul 22
NVCR
Earnings call transcript
2022 Q1
28 Apr 22
NVCR
Earnings call transcript
2021 Q4
24 Feb 22
NVCR
Earnings call transcript
2021 Q3
28 Oct 21
NVCR
Earnings call transcript
2021 Q2
29 Jul 21
NVCR
Earnings call transcript
2021 Q1
29 Apr 21
NVCR
Earnings call transcript
2020 Q4
25 Feb 21
NVCR
Earnings call transcript
2020 Q3
29 Oct 20
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 115.83 mm | 115.83 mm | 115.83 mm | 115.83 mm | 115.83 mm | 115.83 mm |
| Cash burn (monthly) | 42.73 mm | 7.81 mm | 14.33 mm | 7.79 mm | 1.24 mm | (no burn) |
| Cash used (since last report) | 115.42 mm | 21.11 mm | 38.69 mm | 21.04 mm | 3.34 mm | n/a |
| Cash remaining | 414.67 k | 94.73 mm | 77.14 mm | 94.80 mm | 112.50 mm | n/a |
| Runway (months of cash) | 0.0 | 12.1 | 5.4 | 12.2 | 91.0 | n/a |
Institutional ownership, Q4 2022
80.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 309 |
| Opened positions | 58 |
| Closed positions | 44 |
| Increased positions | 93 |
| Reduced positions | 85 |
| 13F shares | Current |
|---|---|
| Total value | 6.16 tn |
| Total shares | 84.58 mm |
| Total puts | 2.03 mm |
| Total calls | 1.32 mm |
| Total put/call ratio | 1.5 |
| Largest owners | Shares | Value |
|---|---|---|
| FMR | 15.74 mm | $1.15 tn |
| Capital World Investors | 12.85 mm | $942.50 bn |
| Vanguard | 9.55 mm | $700.30 bn |
| Baillie Gifford & Co | 8.86 mm | $650.16 bn |
| Capital International Investors | 7.95 mm | $583.23 bn |
| BLK Blackrock | 7.61 mm | $557.87 bn |
| STT State Street | 2.24 mm | $164.13 bn |
| T. Rowe Price | 2.17 mm | $158.83 bn |
| Nordwand Advisors | 1.52 mm | $111.13 bn |
| Geode Capital Management | 1.35 mm | $98.91 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Mar 23 | Frank X Leonard | Ordinary Shares | Sell | Dispose S | No | Yes | 75.5937 | 2,315 | 175.00 k | 54,284 |
| 7 Mar 23 | Frank X Leonard | Ordinary Shares | Sell | Dispose S | No | Yes | 74.9968 | 6,003 | 450.21 k | 56,599 |
| 3 Mar 23 | Uri Weinberg | Ordinary Shares | Grant | Acquire A | No | No | 0 | 3,936 | 0.00 | 89,044 |
| 3 Mar 23 | Uri Weinberg | Ordinary Shares | Grant | Acquire A | No | No | 0 | 28,830 | 0.00 | 85,108 |
| 3 Mar 23 | Ashley Cordova | Ordinary Shares | Sell | Dispose S | No | No | 76.1594 | 775 | 59.02 k | 101,310 |
| 3 Mar 23 | Ashley Cordova | Ordinary Shares | Sell | Dispose S | No | No | 76.1594 | 4,730 | 360.23 k | 102,085 |
| 3 Mar 23 | William Patrick Burke | Ordinary Shares | Sell | Dispose S | No | No | 76.1594 | 593 | 45.16 k | 66,090 |
| 3 Mar 23 | Frank X Leonard | Ordinary Shares | Sell | Dispose S | No | No | 76.1594 | 888 | 67.63 k | 62,602 |
| 3 Mar 23 | Frank X Leonard | Ordinary Shares | Sell | Dispose S | No | No | 76.1594 | 4,403 | 335.33 k | 63,490 |
| 3 Mar 23 | Wilhelmus CM Groenhuysen | Ordinary Shares | Sell | Dispose S | No | No | 76.1594 | 20,415 | 1.55 mm | 209,753 |
News
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
17 Mar 23
What 4 Analyst Ratings Have To Say About NovoCure
17 Mar 23
JP Morgan Downgrades NovoCure to Underweight, Lowers Price Target to $50
17 Mar 23
Novocure Announced A Grant Of $1.5M For The Tumor Treating Fields Research Program
16 Mar 23
Novocure Has Enrolled The Final Patient In The Pivotal METIS Study Evaluating The Efficacy Of Tumor Treating Fields (TT Fields) Therapy Following Stereotactic Radiosurgery For Brain Metastases Resulting From Non-small Cell Lung Cancer
1 Mar 23
Press releases
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
16 Mar 23
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
1 Mar 23
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
1 Mar 23
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
23 Feb 23
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
15 Feb 23